SAEN net incomeFY2025-€6.53M
SAEN net income was -€6.53M for fiscal 2025 (ended Dec 31, 2025), compared with -€8.91M in fiscal 2024.
Genenta Science S.p.A. (SAEN) financials
For fiscal 2025 (ended Dec 31, 2025), Genenta Science S.p.A. reported -€6.53M of net income. Figures are in EUR, the currency of its SEC filings.
- Net income, FY2025
- -€6.53M
- Free cash flow, FY2025
- -€6.88M
- EPS, diluted, FY2025
- -€0.33
- Cash
- €5.53M
FY2019FY2025
FY2020FY2025
SAEN revenue and earnings growth
SAEN EPSFY2025-€0.33
SAEN diluted EPS was -€0.33 for fiscal 2025 (ended Dec 31, 2025), compared with -€0.49 in fiscal 2024.
SAEN free cash flowFY2025-€6.88M
SAEN free cash flow was -€6.88M for fiscal 2025 (ended Dec 31, 2025), compared with -€6.24M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | €2.70M | €4.81M | €6.47M | €5.34M | €3.39M | €4.69M | €3.70M |
| Selling, general and admin | €3.90M | €4.95M | €5.26M | €5.71M | €2.30M | €901.8K | €921.5K |
| Operating income | -€6.60M | -€9.76M | -€11.73M | -€11.04M | -€5.69M | -€5.59M | -€4.62M |
| Pre-tax income | -€6.53M | -€8.91M | -€11.65M | -€8.48M | -€5.53M | -€5.59M | -€4.60M |
| Net income | -€6.53M | -€8.91M | -€11.65M | -€8.48M | -€5.53M | -€5.59M | -€4.60M |
| EPS, basic | - | - | -€0.64 | -€0.47 | -€0.37 | - | - |
| EPS, diluted | -€0.33 | -€0.49 | -€0.64 | -€0.47 | -€0.37 | - | - |
| Diluted shares | 19.7M | 18.3M | 18.2M | 18.2M | 15.1M | - | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | €5.53M | €4.58M | €3.69M | €29.79M | €37.24M | €15.47M | - |
| Short-term investments | €22.62M | €8.08M | €15.08M | - | - | - | - |
| Current assets | €29.98M | €14.47M | €21.26M | €31.72M | €38.76M | €16.53M | - |
| Total assets | €31.89M | €14.82M | €22.35M | €33.44M | €40.03M | €17.50M | - |
| Current liabilities | €2.12M | €2.10M | €1.74M | €2.18M | €1.14M | €2.33M | - |
| Shareholders' equity | €21.84M | €12.50M | €20.43M | €31.14M | €38.86M | €15.15M | €18.85M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -€6.87M | -€6.24M | -€11.21M | -€7.42M | -€6.96M | -€6.04M | -€2.49M |
| Capital expenditures | €7.6K | €4.5K | €13.8K | €27.1K | €9.0K | €20.9K | - |
| Free cash flow | -€6.88M | -€6.24M | -€11.22M | -€7.45M | -€6.97M | -€6.07M | - |
| Investing cash flow | -€14.54M | €6.88M | -€14.89M | -€27.1K | -€9.0K | -€20.9K | - |
| Financing cash flow | €22.29M | €270.9K | €531 | - | €28.74M | €1.39M | €14.77M |
| Stock-based compensation | €1.01M | €847.3K | €739.9K | €722.7K | €497.1K | €460.2K | €749.5K |
| Depreciation and amortization | €28.1K | €44.5K | €42.5K | €6.1K | €4.9K | €1.9K | - |
Key ratios
Source: XBRL data Genenta Science S.p.A. files with the SEC, latest filing dated Apr 1, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
SAEN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SAEN | - | - | -€6.53M | - | $30.4M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $253.21B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.52B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $100.63B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $60.67B |
| RVMD | $0 | - | -$1.13B | - | $39.08B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.46B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $22.02B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $17.65B |
SAEN FAQ
6 questionsIs SAEN profitable?
No. Genenta Science S.p.A. reported a net loss of €6.53M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does SAEN have?
Genenta Science S.p.A. reported €5.53M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is SAEN free cash flow?
Genenta Science S.p.A. generated -€6.88M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -€6.87M less capital expenditures.What is SAEN earnings per share?
Diluted earnings per share were -€0.33 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did SAEN last report financial results?
The latest statements here come from Genenta Science S.p.A.'s 20-F filed on Apr 1, 2026, covering the period ended Dec 31, 2025.Where does this SAEN financial data come from?
Quantisnow builds these statements from the structured XBRL data Genenta Science S.p.A. files with the SEC. It is provided for information only and is not investment advice.